1 / 17

A.D. Roth, R. Biffi, R. Stupp, R. Morant, J.C. Schuller, F. De Braud, O. Huber, N. Fazio

Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO).

evangeline-phelps
Download Presentation

A.D. Roth, R. Biffi, R. Stupp, R. Morant, J.C. Schuller, F. De Braud, O. Huber, N. Fazio

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO) A.D. Roth, R. Biffi, R. Stupp, R. Morant, J.C. Schuller, F. De Braud, O. Huber, N. Fazio SAKK 43/99 Barcelona 2007

  2. Background • Adjuvant chemotherapy has been reported as minimally effective in the curative treatment of gastric cancer • Adjuvant chemotherapy is often difficult to start on time and to conduct after gastrectomy because of delayed recovery • Neoadjuvant chemotherapy has been shown to be feasible and to induce tumor response before surgery (Van Cutsem et al, Ann Oncol 2006) • Very short time to response are highly desirable in this setting and can be obtained with docetaxel containing regimens (Roth AD et al, J Clin Oncol 2007)

  3. Objectives • To compare the feasibility in term of tolerance and toxicity of the same chemotherapeutic regimen administered in an adjuvant and neoadjuvant setting in a randomized phase III trial • To evaluate the efficacy and tolerance of a docetaxel based combination used with surgery in the curative treatment of locally advanced gastric cancer

  4. Methods • Patient inclusion criteria • Locally advanced resectable gastric cancer (LARGC) T2N+M0 or T3-4anyN M0 • PS ≤2, normal blood count, normal renal and hepatic functions • Absence of macroscopic peritoneal carcinomatosis • Staging work up • Body CT-scan • Gastroscopy with echoendoscopy • Bone scintigraphy • Peritoneal lavage and/or laparoscopy

  5. Treatment TCF X 4 Surgery (arm A) T2N+M0 T3-4anyN M0 Surgery TCF X 4 (arm B) • TCF: • Docetaxel 75mg/m2 d1 • Cisplatin 75 mg/m2 d1 • 5-Fluouracyl 300mg/m2 in continuous infusion d1-14 • Repeat cycle every 3 weeks R

  6. Statistical considerations • The trial was planned to recruit 252 patients allowing to detect 15% difference in event free rate at 3 years (arm A 35%, arm B 20%) but was interrupted due to slow accrual after 70 patients were enrolled • Tolerance and toxicity results are compared between the 2 arms. Analyses are exploratory, p-value are two sided and not adjusted for multiple testing

  7. Patient Characteristics

  8. S =>TCF N = 35 Preop CT (4 cycles) Started N=33 (97%) Completed N= 25 (74%) Surgery N = 32 (94%) Surgery N = 35 (100%) Postop CT (4 cycles) Started N = 23 (66%) Completed N = 12 (34%) Trial profile TCF => S N = 34 pCR in 4 patients (12.9%)

  9. Intensity of treatment administered per arm ‡ p<0.05, € p=0.07, # p<0.001, + p<0.003, * p<0.0003 ¥ Dose intensity corrected to actually given cycles

  10. Hematotoxicity (NCIC grade 3/4) Arm A Arm B (% per patient / % per cycle) • Neutropenia 79%/41% 61%/34% • Thrombocytopenia 0% 4%/1% • Febrile neutropenia 15%/8% 9%/3%

  11. Non-hematological toxicity (NCIC grade 3/4) Arm A Arm B (% per patient / % per cycle) Nausea/vomiting 3%/1% 13%/4% Alopecia 55%/ - 35%/ - Diarrhea 9%/3% 4%/3% Stomatitis 0% 9%/3% Neurosensory 0% 0% Neuromotor 0% 0% Plantar-palmar 0% 0% Other skin 0% 0%

  12. Discussion • This is the only available trial comparing head to head the feasibility and tolerability of the same systemic regimen in a neoadjuvant and adjuvant setting • Neoadjuvant chemotherapy is feasible in gastric cancer while adjuvant chemotherapy is difficult to conduct after gastrectomy • Our data are consistent withthe results of the published trials of perioperative chemotherapy in gastric cancer (MAGIC trial [NEJM july 2006] and FNLCC-ACCORDtrial [ASCO 2007 abstr #4510])

  13. Perioperative chemotherapy for locally advanced Gastric Cancer:The MAGIC and the French trials Surgery alone Stage ≥II Chemoth Surgery Chemoth • MAGIC trial: ECF x 3 => Surgery => ECF x 3 (Total 503 pts) • French trial: FuP x 2 => Surgery => FuP x 4 (Total 224 pts) R

  14. MAGIC trial: Compliance to chemotherapy(Cunningham, D. NEJM 355: 11-20 2006) • Preop. chemotherapy: • Started: 237 pts • Completed 3 cycles: 215 pts (90.7%) • Surgery: 209 pts • Postop. Chemotherapy: • Started: 137 pts (65.6%) • Completed 3 cycles: 104 pts (49.7%)

  15. S N = 111 Preop CT (2-3 cycles) N = 98 (87%) Surgery N = 109 (96%) Surgery N = 110 (99%) Postop CT (1-4 cycles) N = 54 (50%) Trial profile CT + S N = 113 (Boige V. ASCO 2007, abstr #4510)

  16. Nutritional status after total gastrectomy • 23 patients followed during 6 mois after gastrectomy 1st month 6th month Mean calory intake (kcal/j) 1 ’458 2 ’118 Insufficient intake* (patients)23/239/23 *according to RDA (Recommended dietary allowance) Braga M. et al Br. J. Surg. 75:477-80 (1988)

  17. Conclusions • In the multidisciplinary approach to the cure of locally advanced gastric cancer a neo-adjuvant strategy should be preferred to an adjuvant strategy whenever possible • Additional trials establishing the role of neoadjuvant (radio-)chemotherapy in the curative approach of gastric cancer are warranted

More Related